《新股表現》C-LINK SQ(01463.HK)暗盤開報0.76元 高上市價20.6%
根據輝立交易平台顯示,明天掛牌的C-LINK SQ(01463.HK)暗盤高開20.6%報0.76元,高見0.95元,現造0.85元,較上市價0.63元,高35%,成交129萬股。
C-LINK SQ為馬來西亞軟件解決方案開發商。是次來港上市共發售2億股,其中10%公開發售獲逾10倍超購,認購一手中籤率僅13%,股份以招股範圍(0.63-0.73元)下限定價,料集資淨額7,580萬元,主要用作增加公司技術實力以發展其他垂直/平行市場能力、擴展其本地市場份額及探索區域擴張等。上市獨家保薦人中毅資本。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.